News

Moonlake’s lead drug Sonelokimab is being tested across inflammatory conditions, with the biggest near-term focus on hidradenitis suppurativa.

The company is promising a new era of accelerated growth, but the trajectory of one key cancer drug holds a subtle warning for investors.

Management once made manufacturing its top priority; now that the topic has gone quiet, it reveals just how much the company's multi-billion-dollar bet has fundamentally changed.

Gilead Sciences won FDA acceptance for a filing that could expand Yeztugo into a once-weekly oral HIV prevention option, broadening its HIV portfolio.

SpaceX’s $75 billion initial public offering shattered market records, turned founder Elon Musk into the world’s first trillionaire, and opened fresh debates over corporate valuations and governance. It’s not the first time an IPO has shaken things up. IPOs have been reshaping markets since the Bank of North America’s 1783 debut got it all started for the young republic.

Gilead seeks FDA approval for once-weekly oral Yeztugo for HIV prevention, aiming to expand access with a new long-acting PrEP option.

Gain insight on Roche, Zealand Pharma and more in the latest Market Talks covering the health care sector.

AZN shares fell after a camizestrant setback, but blockbuster drugs, oncology growth and a deep pipeline support long-term targets.

They have a habit of consistently raising their payouts.

In the last week, the United States market has stayed flat, yet it has seen a significant increase of 24% over the past year with earnings forecasted to grow by 19% annually. In this context, identifying stocks that are estimated to be undervalued can offer investors potential opportunities for capitalizing on price discrepancies relative to their fair value.

Over the last 7 days, the United States market has remained flat, yet it is up 24% over the past year with earnings anticipated to grow by 19% annually in the coming years. In this context of robust growth expectations, identifying stocks that are trading below their intrinsic value can present opportunities for investors seeking potential long-term gains.

We recently published Jim Cramer Didn’t Hold Back On SpaceX’s IPO & Discussed These 12 Stocks. Johnson & Johnson (NYSE:JNJ) is one of the stocks discussed by Jim Cramer. Johnson & Johnson (NYSE:JNJ)’s shares are up by 53% over the past year and by 15% year-to-date. Leerink Partners discussed the firm on May 13th as […]

While the market fixates on the STELARA patent cliff, the rest of the business is quietly accelerating. Excluding the legacy drug, Johnson & Johnson (JNJ) grew in double digits for the quarter. The Innovative Medicine segment absorbed a massive 920 basis point headwind from STELARA, yet still posted 7.4% growth. This is not a company treading water, but a portfolio already hitting its next stride.

For investors considering whether Merck at around US$120.76 still offers value or whether most of the upside is already reflected in the price, this article walks through the key checks investors often rely on. With the stock showing returns of 0.4% over 7 days, 7.5% over 30 days, 13.4% year to date and 53.0% over 1 year, many holders are now asking whether the current price fairly reflects the business. Recent headlines around Merck have focused on its position as a major pharmaceuticals...

Healthcare stocks edged lower late Friday afternoon, with the NYSE Healthcare Index and the State St

Management raised the bar two months ago, but the stock just shrugged. Here’s why the market is waiting for proof, not promises.

Eli Lilly's obesity drug franchise is a juggernaut, but a surprisingly large share of its success relies on price-sensitive consumers.

BMY's growth portfolio now drives more than half of revenues, with strong gains from Reblozyl, Breyanzi and Cobenfy helping offset legacy drug declines.

Based on the average brokerage recommendation (ABR), Merck (MRK) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Phibro Animal Health unit drove 74% of fiscal 2025 revenue, fueled by MFA, vaccines and global expansion, helping offset pressure in other businesses.

Merck Animal Health has agreed to acquire TARGAN, a biodevice company focused on poultry solutions. The deal adds automated, technology driven tools aimed at the poultry sector to Merck's animal health offering. This marks a further step for Merck into animal health technologies alongside its human medicines business. Merck (NYSE:MRK) is drawing fresh attention after its animal health unit moved to acquire TARGAN, a poultry focused biodevice developer. With the share price at $120.76 and a...

In the closing of the recent trading day, Merck (MRK) stood at $120.76, denoting a +1.4% move from the preceding trading day.

Gilead Sciences Inc. (NASDAQ:GILD) is one of the top large cap value stocks to buy now. On June 8, Gilead Sciences and Merck announced positive topline results from two Phase 3 clinical trials, ISLEND-1 and ISLEND-2, evaluating their investigational once-weekly oral HIV treatment. The regimen, which combines islatravir and lenacapavir, successfully met its primary efficacy […]

Before the stock surged, management was laying out a multi-billion-dollar growth story that directly contradicted consensus estimates, if you knew where to look.

Pharma and biotech dealmaking is surging in 2026 as companies pursue acquisitions to expand pipelines, strengthen portfolios and drive growth.

Merck, Southern Company, Lumentum and Peoples Bancorp of North Carolina are highlighted for growth drivers, performance and key risks.

Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.

Phibro trades near 10x forward earnings vs higher peer multiples as strong Q3 beat, margin gains and 2026 guidance support a modest upside case.

Merck, Southern Company and Lumentum lead Zacks' featured research reports as growth drivers, expansion plans and key risks shape outlooks.

While Pyxis Oncology, Inc. (NASDAQ:PYXS) has gained 54.78% year-to-date, analysts continue to see 293.30% upside, helping it secure a spot on our list of hot biotech stocks under $5 to buy. That analyst conviction is rooted in a busy clinical calendar, with key data readouts from Pyxis Oncology, Inc. (NASDAQ:PYXS)’s lead program expected across the […]